1. Home
  2. IMRN vs BGMS Comparison

IMRN vs BGMS Comparison

Compare IMRN & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.77

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Logo Bio Green Med Solution Inc.

BGMS

Bio Green Med Solution Inc.

N/A

Current Price

$0.97

Market Cap

5.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
IMRN
BGMS
Founded
1994
1996
Country
Australia
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.0M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
IMRN
BGMS
Price
$0.77
$0.97
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
20.2K
146.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$137.21
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.74
52 Week High
$2.38
$6.70

Technical Indicators

Market Signals
Indicator
IMRN
BGMS
Relative Strength Index (RSI) N/A 39.77
Support Level N/A $0.74
Resistance Level N/A $1.66
Average True Range (ATR) 0.00 0.12
MACD 0.00 0.01
Stochastic Oscillator 0.00 43.71

Price Performance

Historical Comparison
IMRN
BGMS

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

About BGMS Bio Green Med Solution Inc.

Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

Share on Social Networks: